Acrux Ltd
ASX:ACR
Net Margin
Acrux Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Acrux Ltd
ASX:ACR
|
6.1m AUD |
-149%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
676.5B USD |
26%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
433.1B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.5B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.8B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199B CHF |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
36%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
219.2B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.9B USD |
17%
|
Acrux Ltd
Glance View
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a portfolio of generic topical prescription pharmaceutical products which use dermal and transdermal drug delivery technology. The firm's product pipeline includes Evamist, Lenzetto, Jublia, EMLA and Testosterone Topical Solution. The firm's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The products offered by the Company are the testosterone topical solution to treat adult males who have low or no testosterone and Estradiol MDTS to treat moderate to severe hot flushes commonly associated with menopause. The company is also developing a range of topical and dermatological generic products for the United States market. The firm operates in the United States, Europe and other markets.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Acrux Ltd's most recent financial statements, the company has Net Margin of -148.5%.
You don't have any saved screeners yet